The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Reducing the risk of leaflet thrombosis in transcatheter aortic valve-in-valve implantation by BASILICA: a computational simulation study

EuroIntervention 2019;15:67-70. DOI: 10.4244/EIJ-D-19-00048

1. The DU Cardiovascular Biomechanics Laboratory, Department of Mechanical and Materials Engineering, University of Denver, Denver, CO, USA; 2. University of Washington, Seattle, WA, USA

Leaflet thrombosis of bioprosthetic aortic valves is an increasingly recognised complication1. Subclinical leaflet thrombosis is more commonly observed following transcatheter aortic valve implantation (TAVI) and valve-in-valve (ViV) procedures than in surgical aortic valve replacement1. Anticoagulation therapy with warfarin, as compared with dual antiplatelet therapy, was associated with a decrease in the incidence of reduced leaflet motion in these patients1. However, bleeding is a complication of anticoagulation therapy, and recurrence of reduced leaflet motion has been observed following discontinuation of the anticoagulation therapy. Therefore, minimising the thrombogenicity of transcatheter aortic valves (TAVs) besides the pharmacological prevention methods is essential ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
The Allegra transcatheter heart valve: European multicentre experience with a novel self-expanding transcatheter aortic valve